Publications
SELECTED PUBLICATIONS OF DR. MUNOZ ABOUT NK-1R, SUBSTANCE P & CANCER (SINCE 2004):
2023 - Journal of Clinical Medicine (co-corresponding author)
Neurokinin-1 Receptor Antagonists as a Potential Novel Therapeutic Option for Osteosarcoma Patients Journal of Clinical Medicine.
2022 - Biomed Research International (corresponding author)
The Neurokinin-1 Receptor Is Essential for the Viability of Human Glioma Cells: A Possible Target for Treating Glioblastoma
2019 - Letters in Drug Design & Discovery (1st & corresponding author)
Neurokinin-1 Receptor Antagonists as Anticancer Drugs.
2019 - Molecular and Clinical Oncology (1st & corresponding author)
Neurokinin-1 receptor antagonist aprepitant and radiotherapy, a successful combination therapy in a patient with lung cancer: A case report.
2018 - Investigational New Drugs (corresponding author)
uman acute myeloid leukemia cells express Neurokinin-1 receptor, which is involved in the antileukemic effect of Neurokinin-1 receptor antagonists.
2014 - Journal of Biosciences (1st & corresponding author)
The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs. Journal of Biosciences
2014 - International Journal of Oncology (1st & corresponding author)
The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer.
2014 - Amino Acids (1st & corresponding author)
Involvement of substance P and the NK-1 receptor in human pathology.
2010 - Investigational New Drug (1st & corresponding author)
The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug.
2004 - Archives Italiennes de Biologie (1st & corresponding author)
Antitumoural action of L-733,060 on neuroblastoma and glioma cell lines.